Alphen aan den Rijn, May 1, 2024 – Wolters Kluwer, a global leader in professional information, software
solutions and services, today releases its first-quarter 2024 trading update.
Highlights
? Full-year 2024 guidance reiterated.
? First-quarter revenues up 6% in constant currencies and up 6% organically.
? Recurring revenues (82%) up 7% organically; non-recurring revenues up 1% organically.
? Expert solutions revenues (59%) up 8% organically.
? Cloud software revenues (18%) up 16% organically.
? First-quarter adjusted operating profit margin increased.
? First-quarter adjusted free cash flow increased in constant currencies.
? Net debt-to-EBITDA was 1.4x as of March 31, 2024.
? 2024 share buyback: €353 million of intended share buyback of €1 billion completed in the year through
April 29, 2024.
Nancy McKinstry, CEO and Chair of the Executive Board, commented: “We’ve had a good start to the year,
with 6% organic growth and improvements in the margin and free cash flow. We continued to invest in
scaling our expert solutions, rolling out several new products, and expanding into adjacent markets. And, we
are increasing our investment in deploying artificial intelligence to bring benefits to customers. I am pleased
to reiterate our full-year guidance.”
First-quarter 2024 developments
First-quarter revenues increased 5% in reporting currencies, reflecting organic growth of 6% (1Q 2023: 6%),
slightly offset by the impact of currency due to the weaker U.S. dollar compared to a year ago (average
EUR/USD rate was €/$1.09 in 1Q 2024 versus €/$1.07 in 1Q 2023).
Recurring revenues (82% of revenues), which include subscriptions and other repeating revenue streams,
sustained 7% organic growth (1Q 2023: 7%). Non-recurring revenues (18% of revenues) increased 1%
organically, slowing slightly compared to a year ago (1Q 2023: 2%). Within non-recurring revenues,
transactional revenues posted 3% organic growth (1Q 2023: 1% decline), as Financial & Corporate
Compliance transactional trends started to stabilize and Legal & Regulatory transactional revenues (ELM
Solutions) remained strong. Organic growth in software license and implementation fees and other non-
recurring revenues slowed to 1% (1Q 2023: 2%). The adjusted operating profit margin increased in the first
quarter compared to first quarter 2023.
Health revenues increased 7% in constant currencies and 7% organically (1Q 2023: 5%). Clinical Solutions
delivered 9% organic growth (1Q 2023: 6%), reflecting good renewal rates in clinical decision support and
clinical drug information. Our referential drug data and patient engagement solutions (formerly Lexicomp
and Emmi) were brought under the UpToDate brand. Health Learning, Research & Practice recorded 5%
organic growth (1Q 2023: 3%), benefitting from new journal launches, including NEJM AI, a title focused on AI
in Medicine.
Tax & Accounting revenues increased 6% in constant currencies, with organic growth of 8% (pro forma
1Q 2023: 9%) partly offset by the transfer of our Chinese legal research solution Bold (2023 revenues:
€21 million) to the Legal & Regulatory division. North American organic growth slowed to 8% as expected
(pro forma 1Q 2023: 11%) partly due to the challenging comparable created by last year’s tax guide
publication schedule. Europe recorded a strong start to the year despite the absence of last year’s one-time
benefits in Germany and Spain. Asia Pacific & Rest of World grew 2% organically (1Q 2023: 7%) as print books
turned down.
Financial & Corporate Compliance revenues grew 4% in constant currencies and 4% organically (pro forma
1Q 2023: 2%). Recurring revenues increased 6% organically (pro forma 1Q 2023: 5%). Transactional and other
non-recurring revenues began to stabilize (1% organic increase in 1Q 2024 compared to pro forma decline of
4% in 1Q 2023) but remain difficult to predict. Legal Services grew 4% organically (pro forma 1Q 2023: 2%),
supported by sustained organic growth in service subscriptions alongside stable transactional revenues.
Financial Services revenues grew 3% organically (pro forma 1Q 2023: 1%), supported by 4% organic growth in
recurring revenues and a slight upturn in transactional revenues compared to decline a year ago.
Wolters Kluwer First-Quarter 2024 Trading Update Page 2 of 4
Legal & Regulatory revenues grew 8% in constant currencies and 5% organically (pro forma 1Q 2023: 4%),
reflecting the transfer into the division of the Bold legal research solution from the Tax & Accounting
division. Legal & Regulatory Information Solutions grew 4% organically (1Q 2023: 4%), with sustained growth
in digital products more than offsetting decline in print. Legal & Regulatory Software revenues grew 6%
organically (pro forma 1Q 2023: 5%), buoyed by sustained double-digit growth in volume-driven
transactional revenues at ELM Solutions related to the on-boarding of new customers.
Corporate Performance & ESG revenues grew 7% in constant currencies and 7% organically (pro forma
1Q 2023: 10%). Recurring revenues sustained double-digit organic growth, while non-recurring revenues
declined in the quarter. Our EHS/ORM1 unit (Enablon) delivered 8% organic growth (1Q 2023: 22%), driven by
double-digit growth in recurring cloud subscriptions partly offset by decline in non-recurring software
license fees against a challenging comparable. The CCH Tagetik Corporate Performance Management (CPM)
platform delivered 13% organic growth (1Q 2023: 16%), driven by Europe and Asia Pacific & ROW. Our
corporate tax, internal audit (TeamMate), and Finance, Risk & Reporting (OneSumX) units all recorded low
single-digit organic growth in the quarter.
Cash flow and net debt
First quarter cash conversion declined compared to first quarter 2023, as expected, due to a working capital
outflow in the quarter compared to an inflow in first quarter 2023. Adjusted free cash flow increased in
constant currencies, mainly due to favorable timing of financing cost and tax paid in the quarter. A total of
€252 million in cash was deployed towards share repurchases during the quarter. Net acquisition spending
was negligible.
Net debt was €2,499 million as of March 31, 2024, compared to €2,612 million at December 31, 2023. Net-
debt-to-EBITDA, based on rolling twelve-months EBITDA, was 1.4x at the end of March 2024, compared to
1.5x at year-end 2023.
In March, 2024, we issued a new €600 million Eurobond with a 5-year term and 3.250% annual coupon.
Shares outstanding, share buybacks, and dividends
As of March 31, 2024, the number of issued ordinary shares outstanding (excluding 9.3 million shares held in
treasury) was 239.2 million.
In the year to date (through April 29), we have repurchased 2.5 million ordinary shares for a total
consideration of €353 million (average share price €141.86). This includes a block trade of €48.0 million
executed on February 22, 2024, to offset the dilution caused by our incentive share issuance.
For the period starting May 2, 2024, up to and including December 27, 2024, we have engaged third parties to
execute approximately €647 million in share buybacks on our behalf, within the limits of relevant laws and
regulations (in particular Regulation (EU) 596/2014) and Wolters Kluwer’s Articles of Association. For the
period after November 10, 2024, this mandate is subject to authorization by the AGM on May 8, 2024. Share
repurchases will be used for capital reduction purposes through share cancelation. The share repurchase
program may be suspended, discontinued, or modified at any time.
At the Annual General Meeting to be held on May 8, 2024, shareholders will be asked to approve a total
dividend of €2.08 over financial year 2023, an increase of 15% compared to the 2022 dividend. If approved,
the final dividend of €1.36 per share will be paid to shareholders on June 4, 2024 (ADRs: June 11, 2024). The
interim dividend for 2024 will be set at 40% of the 2023 total dividend.
Sustainability developments
Across the group, the focus in early 2024 has been on reinforcing a range of initiatives that foster diversity,
engagement, and belonging, including career development programs and employee networks. Our global
real estate team began executing on plans to deliver a reduction in square meters of office space in 2024,
while at the same time improving the quality of workspaces for employees. These plans will help us reach
our SBTi2 -validated targets.
1 EHS/ORM = environmental, health & safety and operational risk management.
2 SBTi = Science Based Targets initiative.
Wolters Kluwer First-Quarter 2024 Trading Update Page 3 of 4
Full-year 2024 outlook
Our group-level guidance for 2024, shown in the table below, is unchanged. We continue to expect
sustained good organic growth in 2024, in line with the prior year, and a further modest increase in the
adjusted operating profit margin. Due to phasing of investment expenses, margin improvement is expected
to be modest in the first half.
Full-Year 2024 Outlook
Performance indicators 2024 Guidance 2023 Actual
Adjusted operating profit margin* 26.4%-26.8% 26.4%
Adjusted free cash flow** €1,150-€1,200 million €1,164 million
ROIC* 17%-18% 16.8%
Diluted adjusted EPS growth** Mid- to high single-digit 12%
*Guidance for adjusted operating profit margin and ROIC is in reporting currency and assumes an average EUR/USD rate in 2024 of
€/$1.09. **Guidance for adjusted free cash flow and diluted adjusted EPS is in constant currencies (€/$ 1.08). Guidance reflects
share repurchases of €1 billion in 2024.
In 2023, Wolters Kluwer generated over 60% of its revenues and adjusted operating profit in North America.
As a rule of thumb, based on our 2023 currency profile, each 1 U.S. cent move in the average €/$ exchange
rate for the year causes an opposite change of approximately 3 euro cents in diluted adjusted EPS3 .
We include restructuring costs in adjusted operating profit. We expect 2024 restructuring costs to be in the
range of €10-€15 million (FY 2023: €15 million). We expect adjusted net financing costs4 in constant
currencies to increase to approximately €60 million. We expect the benchmark tax rate on adjusted pre-tax
profits to increase and to be in the range of 23.0%-24.0% (FY 2023: 22.9%).
Capital expenditures are expected to remain at the upper end of our guidance range of 5.0%-6.0% of total
revenues (FY 2023: 5.8%). We expect the full-year 2024 cash conversion ratio to be around 95% (FY 2023:
100%) due to lower net working capital inflows.
Our guidance assumes no additional significant change to the scope of operations. We may make further
acquisitions or disposals which can be dilutive to margins, earnings, and ROIC in the near term.
2024 outlook by division
Our guidance for 2024 organic revenue growth by division is summarized below. We expect the increase in
full-year 2024 adjusted operating profit margin to be driven primarily by our Health, Legal & Regulatory,
and Corporate Performance & ESG divisions. The Tax & Accounting margin is expected to decline slightly
due to increased product investment.
Health: we expect full-year 2024 organic growth to be in line with prior year (FY 2023: 6%).
Tax & Accounting: we expect full-year 2024 organic growth to be slightly below prior year (FY 2023: 8%), due
to slower growth in non-recurring outsourced professional services and the absence of one-off favorable
events in Europe.
Financial & Corporate Compliance: we expect full-year 2024 organic growth to be in line with or better than
prior year (FY 2023: 2%) as transactional revenues are expected to stabilize.
Legal & Regulatory: we expect full-year 2024 organic growth to be in line with prior year (FY 2023: 4%).
Corporate Performance & ESG: we expect full-year 2024 organic growth to be better than in the prior year
(FY 2023: 9%) as Finance, Risk & Reporting revenues stabilize.
3 This rule of thumb excludes the impact of exchange rate movements on intercompany balances, which is accounted for in adjusted
net financing costs in reported currencies and determined based on period-end spot rates and balances.
4 Adjusted net financing costs include lease interest charges. Guidance for adjusted net financing costs in constant currencies excludes
the impact of exchange rate movements on currency hedging and intercompany balances.
Wolters Kluwer First-Quarter 2024 Trading Update Page 4 of 4
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for
professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory;
corporate performance and ESG. We help our customers make critical decisions every day by providing
expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180
countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide.
The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext
100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs
are traded on the over-the-counter market in the U.S. (WTKWY).
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube, and
Instagram.
Financial Calendar
May 8, 2024 Annual General Meeting of Shareholders
May 10, 2024 Ex-dividend date: 2023 final dividend
May 13, 2024 Record date: 2023 final dividend
June 4, 2024 Payment date: 2023 final dividend, ordinary shares
June 11, 2024 Payment date: 2023 final dividend ADRs
July 31, 2024 Half-Year 2024 Results
August 27, 2024 Ex-dividend date: 2024 interim dividend
August 28, 2024 Record date: 2024 interim dividend
September 19, 2024 Payment date: 2024 interim dividend
September 26, 2024 Payment date: 2024 interim dividend ADRs
October 30, 2024 Nine-Month 2024 Trading Update
February 26, 2025 Full-Year 2024 Results
March 12, 2025 Publication of 2024 Annual Report.